Symbicort in Chronic Obstruktive Pulmonary Disease
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on March 24, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Disease, Chronic Obstructive
Phase: N/A
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Kai Richter, MD, Study Chair, Affiliation: Medical Department AstraZeneca Germany
Summary
Under daily routine conditions and without any intervention by the sponsor regarding the
selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non-
medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians
(i. e.general practitioners and internists) are asked to document relevant data related to the
budesonide/formoterole therapy in patients with COPD.
Clinical Details
Official title: Symbicort in Chronic Obstruktive Pulmonary Disease
Study design: Cohort, Prospective
Primary outcome: efficacy and tolerability of budesonide /formoterole in subjects with COPD who are treated by general practitioners and internists.
Secondary outcome: to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with COPD treated with budesonide/formoterol
Exclusion Criteria:
- limitiations; possible risks; warnings; contraindications mentioned in the SPC.
Locations and Contacts
Additional Information
Starting date: February 2006
Last updated: February 11, 2008
|
